The polycomb group protein BMI1 is a transcriptional target of HDAC inhibitors

Cell Cycle

Volumn 9, Issue 13, 2010, Pages 2663-2673

  Bommi, Prashant V ^a   Dimri, Manjari ^a   Sahasrabuddhe, Anagh A ^a   Khandekar, Janardan D ^a   Dimri, Goberdhan P ^a  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

BMI1; Breast cancer; c Myc; EZH2; HDAC inhibitors; p57; PcG proteins

Indexed keywords

BMI1 PROTEIN; HISTONE DEACETYLASE INHIBITOR; HISTONE LYSINE METHYLTRANSFERASE; POLYCOMB GROUP PROTEIN;

ARTICLE; BREAST CANCER; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; METASTASIS; PROGNOSIS; PROTEIN EXPRESSION; TARGET CELL; TUMOR GROWTH; UBIQUITINATION;

EID: 77955435095     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.13.12147     Document Type: Article

References (54)

1. Schwartz YB, Pirrotta V. Polycomb silencing mechanisms and the management of genomic programmes. Nat Rev Genet 2007; 8:9-22. (Pubitemid 46006046)
2. Simon JA, Kingston RE. Mechanisms of polycomb gene silencing: knowns and unknowns. Nat Rev Mol Cell Biol 2009; 10:697-708.
3. Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev 2006; 6:846-56. (Pubitemid 44629896)
4. Martinez AM, Cavalli G. The role of polycomb group proteins in cell cycle regulation during development. Cell Cycle 2006; 5:1189-97. (Pubitemid 43845379)
5. Sawa M, Yamamoto K, Yokozawa T, Kiyoi H, Hishida A, Kajiguchi T, et al. BMI-1 is highly expressed in M0-subtype acute myeloid leukemia. Int J Hematol 2005; 82:42-7. (Pubitemid 41512198)
6. Vonlanthen S, Heighway J, Altermatt HJ, Gugger M, Kappeler A, Borner MM, et al. The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer 2001; 84:1372-6. (Pubitemid 32522106)
7. ARF proteins. Cancer Lett 2004; 203:217-24.
8. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005; 115:1503-21. (Pubitemid 40814659)
9. Kim JH, Yoon SY, Jeong SH, Kim SY, Moon SK, Joo JH, et al. Overexpression of Bmi-1 oncoprotein correlates with axillary lymph node metastases in invasive ductal breast cancer. Breast 2004; 13:383-8.
10. Kang MK, Kim RH, Kim SJ, Yip FK, Shin KH, Dimri GP, et al. Elevated Bmi-1 expression is associated with dysplastic cell transformation during oral carcinogenesis and is required for cancer cell replication and survival. Br J Cancer 2007; 96:126-33.
11. Song LB, Zeng MS, Liao WT, Zhang L, Mo HY, Liu WL, et al. Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res 2006; 66:6225-32.
12. Glinsky GV. Death-from-cancer signatures and stem cell contribution to metastatic cancer. Cell Cycle 2005; 4:1171-5.
13. Cao R, Tsukada Y, Zhang Y. Role of Bmi-1 and Ring1A in H2A ubiquitylation and Hox gene silencing. Mol Cell 2005; 20:845-54.
14. Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002; 298:1039-43.
15. Cao R, Zhang Y. SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. Mol Cell 2004; 15:57-67.
16. Ringrose L. Polycomb comes of age: genome-wide profiling of target sites. Curr Opin Cell Biol 2007; 19:290-7.
17. Fiskus W, Pranpat M, Balasis M, Herger B, Rao R, Chinnaiyan A, et al. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Mol Cancer Ther 2006; 5:3096-104.
18. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nature Rev 2006; 6:38-51.
19. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene 2007; 26:5420-32.
20. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007; 26:5541-52.
21. Gui CY, Ngo L, Xu WS, Richon VM, Marks PA. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA 2004; 101:1241-6.
22. cip1/waf1. Int J Biochem Cell Biol 2007; 39:1367-74.
23. WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 2000; 97:10014-9.
24. CIP1/WAF1 1. Cancer Res 2003; 63:3637-45.
25. Guo WJ, Datta S, Band V, Dimri GP. Mel-18, a polycomb group protein, regulates cell proliferation and senescence via transcriptional repression of Bmi-1 and c-Myc oncoproteins. Mol Biol Cell 2007; 18:536-46.
26. Murray PJ. The primary mechanism of the IL-10-regulated antiinflammatory response is to selectively inhibit transcription. Proc Natl Acad Sci USA 2005; 102:8686-91.
27. Jiang G, Espeseth A, Hazuda DJ, Margolis DM. c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J Virol 2007; 81:10914-23.
28. Skov S, Rieneck K, Bovin LF, Skak K, Tomra S, Michelsen BK, et al. Histone deacetylase inhibitors: a new class of immunosuppressors targeting a novel signal pathway essential for CD154 expression. Blood 2003; 101:1430-8.
29. Wang LG, Liu XM, Fang Y, Dai W, Chiao FB, Puccio GM, et al. De-repression of the p21 promoter in prostate cancer cells by an isothiocyanate via inhibition of HDACs and c-Myc. Int J Oncol 2008; 33:375-80.
30. Xu Y, Voelter-Mahlknecht S, Mahlknecht U. The histone deacetylase inhibitor suberoylanilide hydroxamic acid downregulates expression levels of Bcr-abl, c-Myc and HDAC3 in chronic myeloid leukemia cell lines. Int J Mol Med 2005; 15:169-72.
31. Munro J, Barr NI, Ireland H, Morrison V, Parkinson EK. Histone deacetylase inhibitors induce a senescence-like state in human cells by a p16-dependent mechanism that is independent of a mitotic clock. Exp Cell Res 2004; 295:525-38.
32. Ogryzko VV, Hirai TH, Russanova VR, Barbie DA, Howard BH. Human fibroblast commitment to a senescence-like state in response to histone deacetylase inhibitors is cell cycle dependent. Mol Cell Biol 1996; 16:5210-8.
33. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 1995; 92:9363-7.
34. Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Gene Dev 2007; 21:1050-63.
35. Yang X, Karuturi RK, Sun F, Aau M, Yu K, Shao R, et al. CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells. PLoS One 2009; 4:5011.
36. Yamaguchi K, Lantowski A, Dannenberg AJ, Subbaramaiah K. Histone deacetylase inhibitors suppress the induction of c-Jun and its target genes including COX-2. J Biol Chem 2005; 280:32569-77.
37. Alao JP, Stavropoulou AV, Lam EW, Coombes RC, Vigushin DM. Histone deacetylase inhibitor, trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells. Mol Cancer 2006; 5:8.
38. Hu J, Colburn NH. Histone deacetylase inhibition downregulates cyclin D1 transcription by inhibiting nuclear factor-kappaB/p65 DNA binding. Mol Cancer Res 2005; 3:100-9.
39. Zhou Q, Agoston AT, Atadja P, Nelson WG, Davidson NE. Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells. Mol Cancer Res 2008; 6:873-83.
40. Nowak K, Kerl K, Fehr D, Kramps C, Gessner C, Killmer K, et al. BMI1 is a target gene of E2F-1 and is strongly expressed in primary neuroblastomas. Nucleic Acids Res 2006; 34:1745-54.
41. Dimri GP. What has senescence got to do with cancer? Cancer Cell 2005; 7:505-12.
42. Bali P, Pranpat M, Swaby R, Fiskus W, Yamaguchi H, Balasis M, et al. Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2. Clin Cancer Res 2005; 11:6382-9.
43. Duan H, Heckman CA, Boxer LM. Histone deacetylase inhibitors downregulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol Cellular Biol 2005; 25:1608-19.
44. Singh TR, Shankar S, Srivastava RK. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene 2005; 24:4609-23.
45. Wang E. Regulation of apoptosis resistance and ontogeny of age-dependent diseases. Exp Geront 1997; 32:471-84.
46. INK4a contributes to the outcome of cancer therapy. Cell 2002; 109:335-46.
47. Bracken AP, Kleine-Kohlbrecher D, Dietrich N, Pasini D, Gargiulo G, Beekman C, et al. The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Gene Dev 2007; 21:525-30.
48. kip2 is a candidate tumor suppressor gene in human breast cancer. BMC Cancer 2008; 8:68.
49. Nijjar T, Wigington D, Garbe JC, Waha A, Stampfer MR, Yaswen P. p57KIP2 expression and loss of heterozygosity during immortal conversion of cultured human mammary epithelial cells. Cancer Res 1999; 59:5112-8.
50. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009; 138:592-603.
51. Dimri M, Naramura M, Duan L, Chen J, Ortega-Cava C, Chen G, et al. Modeling breast cancer-associated c-Src and EGFR overexpression in human MECs: c-Src and EGFR cooperatively promote aberrant three-dimensional acinar structure and invasive behavior. Cancer Res 2007; 67:4164-72.
52. Kia SK, Gorski MM, Giannakopoulos S, Verrijzer CP. SWI/SNF mediates polycomb eviction and epigenetic reprogramming of the INK4b-ARF-INK4a locus. Mol Cell Biol 2008; 28:3457-64.
53. Dimri M, Bommi P, Sahasrabuddhe AA, Khandekar JD, Dimri GP. Dietary omega-3 polyunsaturated fatty acids suppress expression of EZH2 in breast cancer cells. Carcinogenesis 2009.
54. Datta S, Hoenerhoff MJ, Bommi P, Sainger R, Guo WJ, Dimri M, et al. Bmi-1 cooperates with H-Ras to transform human mammary epithelial cells via dysregulation of multiple growth-regulatory pathways. Cancer Res 2007; 67:10286-95.